摘要
Abstract
Objective To investigate the efficacy of ulinastatin combined with somatostatin in the treatment of acute pancreatitis(AP).Methods A total of 72 patients with AP treated at The Second Affiliated Hospital of Zhengzhou University from February 2023 to February 2025 were selected and randomly divided into a control group and a study group using the random number table method,with 36 patients in each group.The control group received somatostatin,while the study group received ulinastatin plus somatostatin.Pancreatic function,levels of inflammatory markers,symptom relief,and adverse reactions were compared between the two groups.Results After 10 days of treatment,the serum amylase and lipase levels in both groups were lower than those before treatment,and the levels in the study group were lower than those in the control group,with statistically significant differences(P＜0.05).After 10 days of treatment,the white blood cell count(WBC),neutrophil percentage(NEUT%),and C-reactive protein(CRP)levels in both groups were lower than those before treatment,and the levels in the study group were lower than those in the control group,with statistically significant differences(P＜0.05).After 10 days of treatment,the Visual Analog Scale(VAS)scores for abdominal pain in both groups were lower than those before treatment,and the score in the study group was lower than that in the control group,with a statistically significant difference(P＜0.05).The times to disappearance of abdominal pain and abdominal distension and the recovery time of anal exhaust were shorter in the study group than in the control group,with statistically significant differences(P＜0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Ulinastatin combined with somatostatin in patients with AP can significantly improve pancreatic function,alleviate the inflammatory response,and does not cause excessive adverse reactions.关键词
急性胰腺炎/乌司他丁/生长抑素/炎症/不良反应Key words
acute pancreatitis/ulinastatin/somatostatin/inflammation/adverse reactions
